Cemiplimab + XL092
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anaplastic Thyroid Cancer
Conditions
Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors
Trial Timeline
Jun 3, 2025 → Aug 31, 2028
NCT ID
NCT06902376About Cemiplimab + XL092
Cemiplimab + XL092 is a phase 1 stage product being developed by Regeneron Pharmaceuticals for Anaplastic Thyroid Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06902376. Target conditions include Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06902376 | Phase 1 | Recruiting |
Competing Products
20 competing products in Anaplastic Thyroid Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CS-7017 + Paclitaxel | Daiichi Sankyo | Phase 1/2 | 41 |
| efatutazone + paclitaxel | Daiichi Sankyo | Phase 2 | 52 |
| Lenvatinib 24 mg | Eisai | Phase 2 | 52 |
| Lenvatinib + Nivolumab | Ono Pharmaceutical | Phase 2 | 52 |
| durvalumab + tremelimumab | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| LDK378 + AUY922 | Novartis | Phase 1 | 33 |
| ceritinib | Novartis | Pre-clinical | 23 |
| LDK378 | Novartis | Phase 1 | 33 |
| Ceritinib | Novartis | Phase 2 | 52 |
| Gemcitabine + ribociclib + sonidegib + trametinib + filgrastim | Novartis | Phase 1 | 33 |
| dabrafenib/trametinib | Novartis | Phase 2 | 52 |
| Trametinib + Paclitaxel | Novartis | Phase 1 | 33 |
| Alectinib + Crizotinib | Roche | Phase 3 | 77 |
| Sunitinib Malate | Pfizer | Phase 2 | 51 |
| Crizotinib (PF-02341066) | Pfizer | Phase 2 | 51 |
| Lorlatinib | Pfizer | Phase 2 | 51 |
| Crizotinib | Pfizer | Phase 1/2 | 40 |
| Etirinotecan pegol | Nektar Therapeutics | Phase 2 | 47 |
| Bevacizumab | Novocure | Phase 2 | 47 |